
    
      The purpose of this study was to evaluate the efficacy and safety of PD-1 monoclonal antibody
      combined with ICE in the treatment of patients with relapsed/refractory gray zone lymphoma.
      The main study endpoint is the Objective Response Rate (ORR), including Complete Remission
      Rate (CRR) and Partial Remission Rate (PRR), was evaluated according to Lugano2014 lymphoma
      efficacy evaluation criteria.
    
  